Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Terminated
1(33%)

Phase Distribution

Ph not_applicable
2
67%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Completed1
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (33.3%)
N/A2 (66.7%)

Trials by Status

completed133%
terminated133%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
completednot_applicable

"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"

NCT05410509
recruitingphase_2

A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

NCT06844357
terminatednot_applicable

LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors

NCT02649868

Clinical Trials (3)

Showing 3 of 3 trials
NCT05410509Not Applicable

"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"

Completed
NCT06844357Phase 2

A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

Recruiting
NCT02649868Not Applicable

LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors

Terminated

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3